Companies
Kääpä Biotech
Mushroom extracts — NordRelease® UAE.
- Country
- Finland
Organic
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Certification | Total funding of approximately €9.9 million, including a €9 million round in November 2025 and a €900,000 round in April 2025 | kaapabiotech.com · mycostories.com · nutraingredients.com |
| Capacity | Company is actively increasing production capacity through recent facility expansions and investment funding | nutraceuticalbusinessreview.com · kaapabiotech.com · mycostories.com · nutraingredients.com |
| Certification | FSSC 22000 certified and holds EU organic certification | kaapabiotech.com · mycostories.com · proteinproductiontechnology.com |
| Regulatory approval | NordRelease extraction process validated by the European Food Safety Authority (EFSA) as non-novel status in April 2025 | kaapabiotech.com · mycostories.com · proteinproductiontechnology.com |
| Production site | Production facilities located in Karjalohja (headquarters), Paimio (opened September 2024), and Salo (opened June 2025), Finland | kaapabiotech.com · mycostories.com · nutraingredients.com |
| Headcount | Approximately 25 to 30 employees as of 2025-2026 | asiakastieto.fi · nutraingredients.com |
| Revenue | Revenue was €2.6 million in 2025; LinkedIn profile reports $5 million annually | asiakastieto.fi |
Independent sources: asiakastieto.fi · mycostories.com · nutraceuticalbusinessreview.com · nutraingredients.com · proteinproductiontechnology.com
Technologies
No articles yet.
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.